Bayesian borrowing in Phase 3 trials formally combines prior evidence with the new trial data to enhance development efficiency and regulatory decision making. This approach requires rigorous statistical modeling, careful selection of historical information, and detailed regulatory dialogue.

Bayesian borrowing in Phase 3 trials formally combines prior evidence with the new trial data to enhance development efficiency and regulatory decision making. This approach requires rigorous statistical modeling, careful selection of historical information, and detailed regulatory dialogue.

In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine Bayesian borrowing in Phase 3 clinical trials, focusing on statistical handling of prior information and real-world FDA interactions.

In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine Bayesian borrowing in Phase 3 clinical trials, focusing on statistical handling of prior information and real-world FDA interactions.

In Episode 51 of "In the Interim…", Dr. Scott Berry interviews writer, producer, and performer Shaun Cassidy to examine the practical elements of storytelling that matter in scientific and statistical communication.

In Episode 51 of "In the Interim…", Dr. Scott Berry interviews writer, producer, and performer Shaun Cassidy to examine the practical elements of storytelling that matter in scientific and statistical communication.